In the treatment of parkinsonism, bromocriptine differs
from levodopa in the following respects except:
A. It does not need conversion to an active
metabolite
B. It has a longer duration of action
C. It activates dopamine D2 receptors, with
little/antagonistic action on D1 receptors
D. It does not produce behavioral/psychiatric
side effect
from levodopa in the following respects except:
A. It does not need conversion to an active
metabolite
B. It has a longer duration of action
C. It activates dopamine D2 receptors, with
little/antagonistic action on D1 receptors
D. It does not produce behavioral/psychiatric
side effect